edoc

Overview: development of drugs against Mycobacterium ulcerans

Pluschke, G. and Röltgen, K.. (2022) Overview: development of drugs against Mycobacterium ulcerans. In: Mycobacterium ulcerans. Methods and protocols, 2387. New York, NY, pp. 185-187.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/91320/

Downloads: Statistics Overview

Abstract

For many years, wide margin surgical excision of Buruli ulcer lesions has been the main approach for the treatment of Mycobacterium ulcerans disease. The WHO now recommends an eight-week course of oral antibiotics with a combination of rifampicin and clarithromycin in Africa. However, disease management is complicated by social stigma, lack of awareness, and limited access to healthcare facilities, resulting in underreporting and frequently late initiation of medical treatment. Inadequate initial treatment can drive permanent disabilities and also limited compliance to the eight-week therapy is a limitation. Therefore, search for a faster and more simple treatment modality is ongoing, focusing primarily on the testing of new tuberculosis drug candidates for the treatment of M. ulcerans disease.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Molecular Immunology (Pluschke)
UniBasel Contributors:Pluschke, Gerd
Item Type:Book Section, refereed
Book Section Subtype:Further Contribution in a Book
Publisher:Humana
ISSN:1940-6029 (Electronic)1064-3745 (Linking)978-1-0716-1778-6978-1-0716-1779-3
Note:Publication type according to Uni Basel Research Database: Book item
Identification Number:
Last Modified:27 Dec 2022 16:50
Deposited On:27 Dec 2022 16:50

Repository Staff Only: item control page